Tessera Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
55 Cambridge Pkwy Ste 800E, Cambridge, M...Phone Number
(857) 356-4700Website
www.tesseratherapeutics.comRevenue
$42.3 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
3
1
1
2
2
About Tessera Therapeutics
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.Explore more
Tessera Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tessera Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Tessera Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Tessera Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Tessera Therapeutics
Tessera Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Tessera Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Tessera Therapeutics launches new products
Funding: Get notified immidiatlly once Tessera Therapeutics has new funding data
Check out if Tessera Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Tessera Therapeutics
Find 2 more new buyers
Compare Similar Companies to Tessera Therapeutics
Compare insights from companies similar to Tessera Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tessera Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tessera Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tessera Therapeutics.
Tessera Therapeutics financials insights
Gather financial insights about Tessera Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$50M
2021
Series B
$230M
2022
Series C
$300M
Tessera Therapeutics Tech Stack
A closer look at the technologies used by Tessera Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Open Position
Person-Based
Bioengineering, Medical Research
Tessera Therapeutics News & Media
Tessera Therapeutics Showcases New Preclinical Data Advancing In Vivo Program in Sickle Cell Disease and CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting
SOMERVILLE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, is presenting updates across its in vivo genetic medicine programs for SCD and T cell therapies, including its proprietary delivery platform that enables extra-hepatic LNP delivery to hematopoietic stem cells (HSCs) and T cells. These data were shared across four presentations at the American Society of Gene and CellTessera Therapeutics to Present New Preclinical Data Supporting In Vivo Program in Sickle Cell Disease and Advancements in In Vivo CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting
SOMERVILLE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced four presentations of new preclinical data at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place in Boston, Massachusetts, May 11 – 15, 2026.Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure
Funding from the Gates Foundation supports development of multiple in vivo Gene Writing strategies aimed at enabling a scalable cure for HIV Funding from the Gates Foundation supports development of multiple in vivo Gene Writing strategies aimed at enabling a scalable cure for HIV
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tessera Therapeutics
Sign Up For FreeTo access detailed company insights
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.... Read More
